Table 1.

Patient Characteristics

	Age	Disease	First diagnosis	Previous surgery	Previous sCT	Associated sCT	PIPAC procedure
Pat 1	62	DMPM	April 2012	2 CRS + HIPEC	1 line	–	2
Pat 2	71	EOC	September 2010	ARR, ovarectomy, hysterectomy, omentectomy, lymphadenectomy	7 lines	Topotecan (days 1, 8, 15)	3
Pat 3	68	CRC	May 2014	Explorative laparotomy	2 lines	Folfox + Cetuximab	4
Pat 4	43	PMP	August 2013	Debulking	2 lines + irinotecan IP	Folfoxiri	4
Pat 5	61	EOC	September 2012	ARR, small bowel resection, ovarectomy, hysterectomy, omentectomy	3 lines	Weekly paclitaxel	3
Pat 6	39	GC	December 2014	Explorative laparotomy	2 lines	Folfiri	3
Pat 7	51	GC	November 2013	Gastric resection	2 lines	Paclitaxel + ramucirumab	3
Pat 8	47	GC	July 2015	Explorative laparoscopy	1 line	Xelox	3
Pat 9	53	EOC	September 2014	Ovarectomy, hysterectomy,	2 lines	Paclitaxel	2
Pat 10	78	DMPM	April 2015	Explorative laparoscopy	1 line	Pemetrexed	3
Pat 11	51	CRC	August 2011	CRS + HIPEC	2 lines	Cetuximab	2
Pat 12	55	GC	January 2015	Gastric resection, omentectomy,	1 line	CDDP + teysuno	2
Pat 13	45	GC	December 2013	Gastric resection	1 line	CDDP + gemcitabine	3
Pat 14	52	GC	July 2015		1 line	Paclitaxel + ramucirumab	3

sCT systemic chemotherapy, CRS cytoreductive surgery, ARR anterior rectal resection, IP intraperitoneal, DMPM diffuse malignant peritoneal mesothelioma, EOC epithelial ovarian cancer, CRC colorectal cancer, PMP pseudomyxoma peritonei, and GC gastric cancer